因此研发新的、敏锐度更高的试验可能弊大于利，因为它们提高了过度诊断率，却无法为患有攻击型癌症的女性带来更多帮助。
Efforts to develop new, more sensitive screening tests are thus likely to do more harm than good, as they increase the rate of over-diagnosis, without improving outcomes among women with aggressive cancers.